006620 — DongKoo Bio & Pharma Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩193bn
- KR₩226bn
- KR₩216bn
- 59
- 58
- 42
- 54
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 125,235 | 139,216 | 155,149 | 194,988 | 215,686 |
Cost of Revenue | |||||
Gross Profit | 70,688 | 80,618 | 92,444 | 117,977 | 132,193 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 118,773 | 131,598 | 147,009 | 177,946 | 201,075 |
Operating Profit | 6,463 | 7,618 | 8,140 | 17,042 | 14,611 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 18,242 | 10,300 | 11,333 | 7,916 | 14,741 |
Provision for Income Taxes | |||||
Net Income After Taxes | 15,101 | 9,140 | 9,327 | 6,614 | 11,808 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 15,101 | 9,140 | 9,327 | 6,614 | 11,812 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 15,101 | 9,140 | 9,327 | 6,614 | 11,812 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 528 | 325 | 229 | 235 | 428 |
Dividends per Share |